Table 1.

Clinical Metadata and Resistance Phenotype Information for the Sequenced Isolates From Cases 1 and 2

Isolate	Case	MLST	cgMLST	cgSNP	Vancomycin	Unit	Daptomycin MIC	Daptomycin Susceptibility	Collection Date	Sequencing Method	Source
UAMSEF_1	1	80	1	1	vanA	E7	≤1 μg/mL	S	6/28/2018	MinION + Illumina	Blood
UAMSEF_2	1	80	2	2	vanA	E7	≤1 μg/mL	S	6/28/2018	Illumina	Blood
UAMSEF_3	1	80	1	1	vanA	E7	2 μg/mL	S	6/29/2018	Illumina	Blood
UAMSEF_4	1	80	2	3	vanA	E7	4 μg/mL	SDD	7/1/2018	Illumina	Blood
UAMSEF_5	1	80	3	4	vanA	E7	4 μg/mL	SDD	7/2/2018	Illumina	Blood
UAMSEF_6	1	80	4	5	vanA	E7	4 μg/mL	SDD	7/3/2018	Illumina	Blood
UAMSEF_7	1	80	1	6	vanA	E7	8 μg/mL	R	7/5/2018	Illumina	Blood
UAMSEF_8	1	80	2	3	vanA	E7	8 μg/mL	R	7/7/2018	MinION + Illumina	Blood
UAMSEF_9	2	80	5	7	vanA	E7	≤1 μg/mL	S	9/18/2018	MinION + Illumina	Blood
UAMSEF_10	2	80	5	8	vanA	E7	≤1 μg/mL	S	9/18/2018	Illumina	Blood
UAMSEF_11	2	80	6	9	vanA	E7	4 μg/mL	SDD	9/19/2018	Illumina	Blood
UAMSEF_12	2	80	6	9	vanA	E7	4 μg/mL	SDD	9/19/2018	Illumina	Blood
UAMSEF_13	2	80	5	7	vanA	E7	4 μg/mL	SDD	9/20/2018	Illumina	Blood
UAMSEF_14	2	80	5	10	vanA	E7	4 μg/mL	SDD	9/20/2018	Illumina	Blood
UAMSEF_15	2	80	6	11	vanA	E7	4 μg/mL	SDD	9/21/2018	Illumina	Blood
UAMSEF_16	2	80	5	7	vanA	E7	4 μg/mL	SDD	9/21/2018	Illumina	Blood
UAMSEF_17	2	80	6	12	vanA	E7	8 μg/mL	R	9/24/2018	Illumina	Blood
UAMSEF_18	2	80	6	11	vanA	E7	8 μg/mL	R	9/24/2018	Illumina	Blood
UAMSEF_19	2	80	5	7	vanA	E7	8 μg/mL	R	9/26/2018	Illumina	Blood
UAMSEF_20	2	80	6	13	vanA	E7	8 μg/mL	R	9/26/2018	MinION + Illumina	Blood

MLST, cgMLST, and cgSNP were performed using 20 isolates (8 from patient 1 and 12 from patient 2).

Abbreviations: cgMLST, core genome multilocus sequence typing; cgSNP, core genome single nucleotide polymorphism; MIC, minimum inhibitory concentration; MLST, multilocus sequence typing; S, Susceptible; R, Resistant; SDD, Susceptible-Dose Dependent.